Catalyst Financial Partners’s DiaMedica Therapeutics DMAC Stock Holding History

Catalyst Financial Partners’s Portfolio DMAC Stock Details DMAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$260K	Hold	38,457	–	–	0.03%	319
2025 Q4	$306K	Hold	38,457	–	–	0.03%	245
2025 Q3	$264K	Hold	38,457	–	–	0.03%	256
2025 Q2	$150K	Hold	38,457	–	–	0.02%	299
2025 Q1	$146K	Hold	38,457	–	–	0.03%	283
2024 Q4	$209K	Hold	38,457	–	–	0.04%	265
2024 Q3	$161K	Hold	38,457	–	–	0.03%	272
2024 Q2	$113K	Buy	38,457 +2,190	+6%	+$6.01K	0.02%	245
2024 Q1	$94.3K	Hold	36,267	–	–	0.02%	226
2023 Q4	$103K	Hold	36,267	–	–	0.03%	215
2023 Q3	$93.6K	Hold	36,267	–	–	0.03%	205
2023 Q2	$157K	Buy	36,267 +11,157	+44%	+$27.1K	0.06%	198
2023 Q1	$38.4K	Buy	25,110 +10,635	+73%	+$16.9K	0.02%	180
2022 Q4	$22.9K	Buy	+14,475	New	+$19.5K	0.01%	161

Other funds holding DMAC

CLG

Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAPAIJV

Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Catalyst Financial Partners's DMAC Position: Q1 2026 in Review

Catalyst Financial Partners held its DiaMedica Therapeutics (DMAC) position steady in Q1 2026 at 38,457 shares worth $260K. The position accounts for 0.03% of the portfolio, ranked #319.

Catalyst Financial Partners first reported a position in DMAC in Q4 2022 and has held it in 14 quarters since. The position peaked at $306K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

Catalyst Financial Partners held 38,457 shares of DiaMedica Therapeutics worth $260K as of Q1 2026.
Catalyst Financial Partners left its DiaMedica Therapeutics share count unchanged in Q1 2026.
DiaMedica Therapeutics made up 0.03% of Catalyst Financial Partners's portfolio in Q1 2026, its #319 holding.
Catalyst Financial Partners first reported a position in DiaMedica Therapeutics in Q4 2022 and has held it in 14 quarters since.
Catalyst Financial Partners's DiaMedica Therapeutics position peaked at $306K in Q4 2025.
98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Catalyst Financial Partners's 13F filing for Q1 2026, filed 12 May 2026.